Stockreport

Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma

Epizyme, Inc.  (EPZM) 
Last epizyme, inc. earnings: 2/24 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: epizyme.com
PDF Durable and Clinically Meaningful Responses Observed in Follicular Lymphoma Patients Regardless of EZH2 Mutational StatusTazemetostat NDA Submission for Follicular Lymph [Read more]